Comprehensive liquid profiling of circulating tumor DNA and protein biomarkers in long-term follow-up patients with hepatocellular carcinoma
Z Cai, G Chen, Y Zeng, X Dong, Z Li, Y Huang… - Clinical Cancer …, 2019 - AACR
Abstract Purpose: Circulating tumor DNA (ctDNA) provides a novel approach for detecting
tumor burden and predicting clinical outcomes of hepatocellular carcinoma (HCC). Here, we …
tumor burden and predicting clinical outcomes of hepatocellular carcinoma (HCC). Here, we …
Protein induced by vitamin K absence or antagonist II: Experience to date and future directions
L Dong, X Qiu, F Gao, K Wang, X Xu - … et Biophysica Acta (BBA)-Reviews on …, 2023 - Elsevier
Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer with high
mortality. The realization of precision medicine in HCC relies upon efficient biomarkers …
mortality. The realization of precision medicine in HCC relies upon efficient biomarkers …
Proteomics-driven noninvasive screening of circulating serum protein panels for the early diagnosis of hepatocellular carcinoma
X Xing, L Cai, J Ouyang, F Wang, Z Li, M Liu… - Nature …, 2023 - nature.com
Early diagnosis of hepatocellular carcinoma (HCC) lacks highly sensitive and specific
protein biomarkers. Here, we describe a staged mass spectrometry (MS)-based discovery …
protein biomarkers. Here, we describe a staged mass spectrometry (MS)-based discovery …
Association of postoperative biomarker response with recurrence and survival in patients with hepatocellular carcinoma and high alpha-fetoprotein expressions (> 400 …
L Liang, MD Wang, YM Zhang, WG Zhang… - Journal of …, 2021 - Taylor & Francis
Background High alpha-fetoprotein (AFP) expressions (> 400 ng/mL) are associated with
poor oncological characteristics for hepatocellular carcinoma (HCC). However, prognosis …
poor oncological characteristics for hepatocellular carcinoma (HCC). However, prognosis …
[HTML][HTML] Identification of potential prognostic markers and key therapeutic targets in hepatocellular carcinoma using weighted gene co-Expression network analysis: A …
H Sharifi, H Safarpour, M Moossavi… - Iranian Journal of …, 2022 - ncbi.nlm.nih.gov
Background: As the most prevalent form of liver cancer, hepatocellular carcinoma (HCC)
ranks the fifth highest cause of cancer-related death worldwide. Despite recent …
ranks the fifth highest cause of cancer-related death worldwide. Despite recent …
Proteomic Analysis Identifies GSN as a Noninvasive Circulating Serum Biomarker for Predicting Early Recurrence of Hepatocellular Carcinoma
E Hu, T Yang, L Cai, J Ouyang, F Wang… - Journal of Proteome …, 2024 - ACS Publications
Hepatocellular carcinoma (HCC) is susceptible to early recurrence, but it lacks effective
predictive biomarkers. In this study, we retrospectively selected 179 individuals as a …
predictive biomarkers. In this study, we retrospectively selected 179 individuals as a …
In silico identification of EP400 and TIA1 as critical transcription factors involved in human hepatocellular carcinoma relapse
W Hong, Y Hu, Z Fan, R Gao, R Yang… - Oncology …, 2020 - spandidos-publications.com
Hepatocellular carcinoma (HCC) is the second leading cause of cancer‑associated mortality
worldwide. Transcription factors (TFs) are crucial proteins that regulate gene expression …
worldwide. Transcription factors (TFs) are crucial proteins that regulate gene expression …
[HTML][HTML] PIVKA-II as a surrogate marker for prognosis in patients with localized hepatocellular carcinoma receiving stereotactic body radiotherapy
IJ Cho, JU Jeong, TK Nam, YE Joo… - Radiation Oncology …, 2022 - ncbi.nlm.nih.gov
Purpose This study aimed to determine the correlation between protein induced by vitamin K
absence or antagonist-II (PIVKA-II) and stereotactic body radiotherapy (SBRT) in patients …
absence or antagonist-II (PIVKA-II) and stereotactic body radiotherapy (SBRT) in patients …
Next-generation des-r-carboxy prothrombin for immunohistochemical assessment of vascular invasion by hepatocellular carcinoma
S Yamazaki, T Takayama, T Kurokawa, N Shimamoto… - BMC surgery, 2020 - Springer
Background We have previously shown the value of next-generation des-r-carboxy
prothrombin (NX-DCP) for predicting vascular invasion in hepatocellular carcinoma (HCC) …
prothrombin (NX-DCP) for predicting vascular invasion in hepatocellular carcinoma (HCC) …
Short Half-Life of Des-γ-Carboxy Prothrombin Is a Superior Factor for Early Prediction of Outcomes of Hepatocellular Carcinoma Treated with Radiofrequency Ablation
CC Yao, JH Wang, CH Chen, CH Hung, YH Yen… - Diagnostics, 2023 - mdpi.com
Background: The role of des-γ-carboxy prothrombin (DCP) in patients undergoing
radiofrequency ablation (RFA) for hepatocellular carcinoma (HCC) needs to be clarified …
radiofrequency ablation (RFA) for hepatocellular carcinoma (HCC) needs to be clarified …